Search
Theriva Biologics Inc
TOVXAdd to Watchlist
0.251USD
+0.001+0.36%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
8.96MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.36%
5 Days
+0.48%
1 Month
-11.15%
6 Months
-2.71%
Year to Date
+19.30%
1 Year
-43.34%
Key Figures
0.255Open
0.261High
718.97KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.01%Turnover Ratio
0.251Prev. Close
0.247Low
125.42KTurnover
LossP/E Static
0.58P/B
0.00%Div Yield TTM
-60.96%ROA
0.86352wk High
1.71Volume Ratio
-25.65MNet Profit
35.69MShares
-0.5754EPS TTM
1.14Beta
-148.69%ROE
0.16352wk Low
5.59%Amplitude
100.00%Gross Margin
8.96MMarket Cap
-1.26Reward/Risk
8.96%Risk Rate
TradingKey Stock Score of Theriva Biologics Inc
Currency: USD Updated: 2026-07-02Key Insights
Theriva Biologics Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 204 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.50.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Theriva Biologics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Theriva Biologics Inc Highlights
StrengthsRisks
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Fairly Valued
The company’s latest PE is -0.44, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.78M shares, increasing 15.72% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.48.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
2.500
Target Price
+897.61%
Upside Space
Theriva Biologics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Theriva Biologics Inc Info
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
Ticker SymbolTOVX
CompanyTheriva Biologics Inc
CEOShallcross (Steven A)
Websitehttps://therivabio.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Theriva Biologics Inc (TOVX)?
The current price of Theriva Biologics Inc (TOVX) is 0.25.
What is the symbol of Theriva Biologics Inc?
The ticker symbol of Theriva Biologics Inc is TOVX.
What is the 52-week high of Theriva Biologics Inc?
The 52-week high of Theriva Biologics Inc is 0.86.
What is the 52-week low of Theriva Biologics Inc?
The 52-week low of Theriva Biologics Inc is 0.16.
What is the market capitalization of Theriva Biologics Inc?
The market capitalization of Theriva Biologics Inc is 8.96M.
Is Theriva Biologics Inc (TOVX) currently rated as Buy, Hold, or Sell?
According to analysts, Theriva Biologics Inc (TOVX) has an overall rating of Buy, with a price target of 2.50.
What is the Earnings Per Share (EPS TTM) of Theriva Biologics Inc (TOVX)?
The Earnings Per Share (EPS TTM) of Theriva Biologics Inc (TOVX) is -2.08.